Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  16 (2024)
Volume  15 (2023)
Volume  14 (2022)
Volume  13 (2021)
Volume  12 (2020)
Volume  11 (2019)
Volume  10 (2018)
Volume  9 (2017)
Volume  8 (2016)
Volume  7 (2015)
Volume  6 (2014)
Volume  5 (2013)
Volume  4 (2012)
Volume  3 (2011)
Volume  2 (2010)
Volume  1 (2009)
Related articles

VOLUME 16 , ISSUE S3 ( December, 2024 ) > List of Articles

CASE REPORT

Embryo Cryopreservation in Ovarian Dysgerminoma: A Case Report

Sumesh Choudhary, Deepa Shah, Rohina Aggarwal, Kunur N Shah, Hardik Sheth

Keywords : Case report, Embryo cryopreservation, Fertility preservation, Oncofertility, Ovarian dysgerminoma

Citation Information :

DOI: 10.5005/jp-journals-10006-2563

License: CC BY-NC 4.0

Published Online: 03-02-2025

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Ovarian dysgerminoma is the most common ovarian malignant germ cell tumor in young females of the reproductive age-group. The disease usually becomes symptomatic and tends to present in its early stages and has decent survival rates with surgery and chemotherapy. This necessitates the need to consider the fertility needs of each patient and timely counsel them about the possibilities for fertility preservation as the survivors may wish to reproduce and that may become an imperative aspect of their post-treatment quality of life. Oocyte and embryo cryopreservation are standard methods of fertility preservation and are well-accepted in selected oncology patients. Timing the fertility-related treatment may play a crucial role considering these patients’ need for further oncological treatment with chemo or radiotherapy. We, with this, present a postoperative case of ovarian dysgerminoma who presented to our IVF center for embryo cryopreservation before chemotherapy.

PDF Share
  1. Talerman A. Germ cell tumors of the ovary. Curr Opin Obstet Gynecol 1997;9(1):44–47. PMID: 9090481.
  2. Smith HO, Berwick M, Verschraegen CF, et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol 2006;107(5):1075–1085. DOI: 10.1097/01.AOG.0000216004.22588.ce.
  3. Ovarian Dysgerminoma. Available from: https://www.yalemedicine.org/clinical-keywords/ovarian-dysgerminoma. [Last accessed November, 2024].
  4. Maidarti M, Garinasih PD, Anggraeni TD. Conservative surgical staging as a means to preserve fertility in patients with dysgerminoma: A case report. Ann Med Surg 2023;85(3):456–459. DOI: 10.1097/ms9.0000000000000146.
  5. Henes M, Neis F, Krämer B, et al. Possibilities of fertility preservation in young patients with ovarian cancer. Anticancer Res 2014;34(7):3851–3854. PMID: 24982413.
  6. Soleimani R, Heytens E, Darzynkiewicz Z, et al. Mechanisms of chemotherapy-induced human ovarian aging: Double-strand DNA breaks and microvascular compromise. Aging (Albany NY) 2011;3(8):782–793. DOI: 10.18632/aging.100363.
  7. Tomao F, Di Pinto A, Sassu CM, et al. Fertility preservation in ovarian tumors. Ecancermedicalscience 2018;12:885. DOI: 10.3332/ecancer.2018.885.
  8. Leblanc E, Narducci F, Ferron G, et al. Indications and teaching of fertility preservation in the surgical management of gynecologic malignancies: European perspective. Gynecol Oncol 2009;114(2 Suppl):S32–S36. DOI: 10.1016/j.ygyno.2009.04.010.
  9. Yahyaei A, Moridi M, Ghaffari F. Controlled ovarian stimulation in cancer patients under 18 years old; A case series. J Ovarian Res 2024;17,33. DOI: 10.1186/s13048-024-01352-0.
  10. Oktay K, Buyuk E, Libertella N, et al. Fertility preservation in breast cancer patients: A prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005;23(19):4347–4353. DOI: 10.1200/JCO.2005.05.037.
  11. Matthews ML, Hurst BS, Marshburn PB, et al. Cancer, fertility preservation, and future pregnancy: A comprehensive review. Obstet Gynecol Int 2012;2012:953937. DOI: 10.1155/2012/953937.
  12. Hu J, Zhu LR, Liang ZQ, et al. Clinical outcomes of fertility-sparing treatments in young patients with epithelial ovarian carcinoma. J Zhejiang Univ Sci B 2011;12(10):787–795. DOI: 10.1631/jzus.B1100166.
  13. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11–30. DOI: 10.3322/caac.21166.
  14. Tangir JA, Schwartz PE. Fertility preservation in the management of germ cell ovarian cancer. CME J. Gynecol. Oncol 2003;8(2):117–20. Available from: https://www.researchgate.net/publication/228485998_Fertility_preservation_in_the_management_of_germ_cell_ovarian_cancer.
  15. Song S. Dysgerminoma. Available from: https://www.pathologyoutlines.com/topic/ovarytumordysgerminoma.html. [Last accessed November,2024].
  16. Zapardiel I, Cruz M, Diestro MD, et al. Assisted reproductive techniques after fertility-sparing treatments in gynecological cancers. Hum Reprod Update 2016;22(3):281–305. DOI: 10.1093/humupd/dmv066.
  17. Salama M, Winkler K, Murach KF, et al. Female fertility loss and preservation: Threats and opportunities. Ann Oncol 2013;24(3):598–608. DOI: 10.1093/annonc/mds514.
  18. Almog B, Azem F, Gordon D, et al. Effects of cancer on ovarian response in controlled ovarian stimulation for fertility preservation. Fertil Steril 2012;98(4):957–960. DOI: 10.1016/j.fertnstert.2012. 06.007.
  19. Perrone AM, Pozzati F, Santini D, et al. Gynecological malignancies and hormonal therapies: Clinical management and recommendations. World J Obstet Gynecol 2014;3(4):162–170. DOI: 10.5317/wjog.v3.i4.162.
  20. Dittrich R, Lotz L, Mueller A, et al. Oncofertility: Combination of ovarian stimulation with subsequent ovarian tissue extraction on the day of oocyte retrieval. Reprod Biol Endocrinol 2013;11:19. DOI: 10.1186/1477-7827-11-19.
  21. Steinkampf MP, Dharia SP, Hammond K. Assisted reproduction in patients with early-stage ovarian malignancies. Fertil Steril 2003;80(6):1510–1512. DOI: 10.1016/s0015-0282(03)02214-3.
  22. Levine JM, Kelvin JF, Quinn GP, et al. Infertility in reproductive-age female cancer survivors. Cancer 2015;121(10):1532–1539. DOI: 10.1002/cncr.29181.
  23. Donnez J, Dolmans MM. Fertility preservation in women. N Engl J Med 2017;377(17):1657–1665. DOI: 10.1056/NEJMra1614676.
  24. von Wolff M, Montag M, Dittrich R, et al. Fertility preservation in women–a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin's lymphoma and borderline ovarian tumors by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet 2011;284(2):427–435. DOI: 10.1007/s00404-011-1874-1.
  25. Ní Dhonnabháin B, Elfaki N, Fraser K, et al. A comparison of fertility preservation outcomes in patients who froze oocytes, embryos, or ovarian tissue for medically indicated circumstances: A systematic review and meta-analysis. Fertil Steril 2022;117(6):1266–1276. DOI: 10.1016/j.fertnstert.2022.03.004.
  26. Fraison E, Huberlant S, Labrune E, et al. Live birth rate after female fertility preservation for cancer or hematopoietic stem cell transplantation: A systematic review and meta-analysis of the three main techniques; Embryo, oocyte, and ovarian tissue cryopreservation. Hum Reprod 2023;38(3):489–502. DOI: 10.1093/humrep/deac249.
  27. Howard-Anderson J, Ganz PA, Bower JE, et al. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: A systematic review. J Natl Cancer Inst 2012;104(5):386–405. DOI: 10.1093/jnci/djr541.
  28. Légaré F, O'Connor AC, Graham I, et al. Supporting patients facing difficult health care decisions: Use of the Ottawa Decision Support Framework. Can Fam Physician 2006;52(4):476–477. PMID: 17327891.
  29. Kim J, Deal AM, Balthazar U, et al. Fertility preservation consultation for women with cancer: Are we helping patients make high-quality decisions? Reprod Biomed Online 2013;27(1):96–103. DOI: 10.1016/j.rbmo.2013.03.004.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.